Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000489884 | SCV000577821 | likely pathogenic | not provided | 2015-04-27 | criteria provided, single submitter | clinical testing | The D269V variant in the IDS gene has been reported in a patient with mucopolysaccharidosis type II (MPS II) (Karsten et al., 1998). The D269V variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The D269V variant is a non-conservative amino acid substitution, which occurs at a position that is conserved across species. However, in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Missense variants in nearby residues (W264D, N265I, N265K, P266H, P266R, and W267C) have been reported in the Human Gene Mutation Database in association with MPS II (Stenson et al., 2014), supporting the functional importance of this region of the protein. The D269V variant is a strong candidate for a disease-causing variant. However, the possibility it may be a rare benign variant cannot be excluded. |
Ambry Genetics | RCV002420251 | SCV002677559 | likely pathogenic | Inborn genetic diseases | 2017-05-08 | criteria provided, single submitter | clinical testing | The p.D269V variant (also known as c.806A>T), located in coding exon 6 of the IDS gene, results from an A to T substitution at nucleotide position 806. The aspartic acid at codon 269 is replaced by valine, an amino acid with highly dissimilar properties. This mutation was identified in two unrelated Portuguese individuals with Hunter syndrome. In addition, this study also demonstrated reduced mRNA levels and IDS enzyme activity in fibroblasts from an affected individual (Alves S et al. J. Inherit. Metab. Dis., 2006 Dec;29:743-54). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV001376700 | SCV005089252 | likely pathogenic | Mucopolysaccharidosis, MPS-II | 2024-06-07 | criteria provided, single submitter | literature only | De novo (PS2_Moderate), In vitro or in vivo functional studies supportive of a damaging effect (PS3_Moderate), Prevalence of the variant significantly increased in affected individuals compared with controls (PS4_Supporting), Absent from controls (or at low frequency) in gnomAD database (PM2_Moderate), Missense variant in a gene with a low rate of benign missense variation (PP2_Supporting), Multiple lines of computational evidence support a deleterious effect (PP3_Supporting), Patient’s phenotype or family history highly specific for the disease (PP4_Moderate) |
Labcorp Genetics |
RCV001376700 | SCV005840547 | pathogenic | Mucopolysaccharidosis, MPS-II | 2024-10-03 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 269 of the IDS protein (p.Asp269Val). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with mucopolysaccharidosis type II (PMID: 10671065, 17063374, 31618753, 35144014). ClinVar contains an entry for this variant (Variation ID: 427181). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt IDS protein function with a negative predictive value of 95%. Studies have shown that this missense change alters IDS gene expression (PMID: 17063374, 28543354). For these reasons, this variant has been classified as Pathogenic. |
Division of Medical Genetics, |
RCV001376700 | SCV001573771 | affects | Mucopolysaccharidosis, MPS-II | 2014-04-02 | no assertion criteria provided | research | The change c.806A>T (p.D269V) was found to be a missense variant, where the acidic polar negative amino acid Aspartic acid at 269 position was substituted by aliphatic nonpolar neutral amino acid Valine. It was detected in a hemizygous state in a single patient with attenuated phenotype from Rajasthan. |